J.P. Morgan discloses Kangji Medical dealings amid privatization

J.P. Morgan Securities PLC, identified as a Class (5) associate connected with the offeror, has disclosed dealings in Kangji Medical Holdings Limited shares. The transaction, dated September 15, 2025, involved the issue of a derivative relating to 5,500 underlying securities. The derivatives have a maturity date of November 3, 2026.

The reference price for this dealing was $8.9041, resulting in a total amount paid/received of $48,972.60. Following this transaction, J.P. Morgan Securities PLC's resultant balance stands at 9,593,642. The dealings were made for J.P. Morgan Securities PLC's own account, which is ultimately owned by JPMorgan Chase & Co.

This disclosure comes in the context of Kangji Medical Holdings Limited's privatization, being executed by way of a scheme of arrangement. The details were released by the Securities and Futures Commission as part of the public disclosure form requirements under Rule 22 of the Hong Kong Code on Takeovers and Mergers.